Citigroup’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.69M | Hold |
30,000
| – | – | ﹤0.01% | 2774 |
|
|
2025
Q4 | $1.78M | Buy |
+30,000
| New | +$1.63M | ﹤0.01% | 2731 |
|
|
2025
Q2 | – | Sell |
-30,000
| Closed | -$2.12M | – | 5660 |
|
|
2025
Q1 | $2.12M | Hold |
30,000
| – | – | ﹤0.01% | 2649 |
|
|
2024
Q4 | $1.97M | Buy |
30,000
+12,800
| +74% | +$857K | ﹤0.01% | 2835 |
|
|
2024
Q3 | $1.21M | Sell |
17,200
-12,800
| -43% | -$1.07M | ﹤0.01% | 3112 |
|
|
2024
Q2 | $2.47M | Buy |
+30,000
| New | +$2.5M | ﹤0.01% | 2171 |
|
|
2023
Q4 | – | Sell |
-35,000
| Closed | -$3.1M | – | 5706 |
|
|
2023
Q3 | $3.1M | Hold |
35,000
| – | – | ﹤0.01% | 1705 |
|
|
2023
Q2 | $3.03M | Buy |
35,000
+5,000
| +17% | +$471K | ﹤0.01% | 1853 |
|
|
2023
Q1 | $2.92M | Buy |
30,000
+10,000
| +50% | +$1.04M | ﹤0.01% | 1777 |
|
|
2022
Q4 | $2.07M | Sell |
20,000
-10,000
| -33% | -$939K | ﹤0.01% | 2011 |
|
|
2022
Q3 | $2.54M | Sell |
30,000
-10,000
| -25% | -$890K | ﹤0.01% | 1976 |
|
|
2022
Q2 | $3.31M | Buy |
+40,000
| New | +$3.18M | ﹤0.01% | 1765 |
|
|
2021
Q1 | – | Sell |
-94,600
| Closed | -$8.29M | – | 6314 |
|
|
2020
Q4 | $8.29M | Sell |
94,600
-100
| -0.1% | -$7.93K | ﹤0.01% | 1714 |
|
|
2020
Q3 | $7.21M | Buy |
94,700
+800
| +0.9% | +$80.9K | ﹤0.01% | 1641 |
|
|
2020
Q2 | $11.6M | Sell |
93,900
-6,900
| -7% | -$686K | 0.01% | 1191 |
|
|
2020
Q1 | $8.52M | Buy |
100,800
+20,800
| +26% | +$1.79M | 0.01% | 1269 |
|
|
2019
Q4 | $6.76M | Buy |
80,000
+7,000
| +10% | +$529K | ﹤0.01% | 1782 |
|
|
2019
Q3 | $4.92M | Buy |
73,000
+15,700
| +27% | +$1.21M | ﹤0.01% | 1961 |
|
|
2019
Q2 | $4.91M | Buy |
57,300
+7,800
| +16% | +$667K | ﹤0.01% | 1996 |
|
|
2019
Q1 | $4.4M | Buy |
49,500
+3,500
| +8% | +$324K | ﹤0.01% | 1910 |
|
|
2018
Q4 | $3.92M | Buy |
46,000
+3,100
| +7% | +$295K | ﹤0.01% | 2046 |
|
|
2018
Q3 | $4.16M | Sell |
42,900
-7,700
| -15% | -$769K | ﹤0.01% | 2044 |
|
|
2018
Q2 | $4.77M | Buy |
50,600
+4,400
| +10% | +$385K | ﹤0.01% | 1877 |
|
|
2018
Q1 | $3.75M | Sell |
46,200
-14,900
| -24% | -$1.28M | ﹤0.01% | 2030 |
|
|
2017
Q4 | $5.45M | Sell |
61,100
-16,900
| -22% | -$1.47M | ﹤0.01% | 1747 |
|
|
2017
Q3 | $7.26M | Sell |
78,000
-85,000
| -52% | -$7.51M | 0.01% | 1453 |
|
|
2017
Q2 | $14.8M | Buy |
163,000
+79,500
| +95% | +$7.23M | 0.01% | 903 |
|
|
2017
Q1 | $7.33M | Sell |
83,500
-200
| -0.2% | -$17.8K | 0.01% | 1373 |
|
|
2016
Q4 | $6.93M | Sell |
83,700
-23,400
| -22% | -$2.01M | 0.01% | 1502 |
|
|
2016
Q3 | $9.91M | Buy |
107,100
+63,400
| +145% | +$5.97M | 0.01% | 1096 |
|
|
2016
Q2 | $3.4M | Buy |
43,700
+7,800
| +22% | +$663K | ﹤0.01% | 1923 |
|
|
2016
Q1 | $2.96M | Sell |
35,900
-3,300
| -8% | -$268K | ﹤0.01% | 2074 |
|
|
2015
Q4 | $4.11M | Sell |
39,200
-111,500
| -74% | -$11.6M | ﹤0.01% | 1869 |
|
|
2015
Q3 | $15.9M | Buy |
150,700
+34,100
| +29% | +$4.55M | 0.01% | 833 |
|
|
2015
Q2 | $15.9M | Buy |
116,600
+104,300
| +848% | +$12.9M | 0.01% | 922 |
|
|
2015
Q1 | $1.53M | Buy |
+12,300
| New | +$1.3M | ﹤0.01% | 2705 |
|
|
2014
Q4 | – | Sell |
-30,000
| Closed | -$2.17M | – | 7111 |
|
|
2014
Q3 | $2.17M | Buy |
+30,000
| New | +$1.97M | ﹤0.01% | 2493 |
|
Other funds holding BMRN
VCM
VPM
Citigroup's BMRN Position: Q1 2026 in Review
Citigroup increased its BioMarin Pharmaceuticals (BMRN) stake by 124% in Q1 2026, buying an estimated $12.7M and bringing the position to 393,895 shares worth $22.3M. The position accounts for 0.01% of the portfolio, ranked #1002.
Citigroup first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $32.7M in Q2 2020. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Citigroup held 393,895 shares of BioMarin Pharmaceuticals worth $22.3M as of Q1 2026.
- Citigroup bought 217,669 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $12.7M.
- BioMarin Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q1 2026, its #1002 holding.
- Citigroup first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Citigroup's BioMarin Pharmaceuticals position peaked at $32.7M in Q2 2020.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.